quinoxalines has been researched along with Rosacea in 19 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 19 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fowler, J; Jackson, M; Jarratt, M; Jones, T; Leoni, M; Meadows, K; Moore, A; Rudisill, D; Steinhoff, M | 1 |
Del Rosso, JQ | 1 |
Kempers, S; Leoni, M; Liu, H; Moore, A; Murakawa, G; Swinyer, L; Tauscher, A; Weiss, J | 1 |
Levitt, JO; Routt, ET | 1 |
Benkali, K; Bouer, R; Fernando, A; Graeber, M; Leoni, M; Rony, F; Wagner, N | 1 |
Berson, D; Del Rosso, JQ; Eichenfield, LF; Gallo, R; Stein-Gold, L; Tanghetti, E; Thiboutot, D; Webster, G; Zaenglein, A | 1 |
Ilkovitch, D; Pomerantz, RG | 1 |
Fowler, J; Jackson, JM; Jarratt, M; Jones, T; Leoni, M; Meadows, K; Moore, A; Rudisill, D; Steinhoff, M | 1 |
Kalowitz, A; Markowitz, O; Meekings, A; Siripunvarapon, AH; Urban, J | 1 |
Moore, AY; Tong, LX | 1 |
Fowler, J | 1 |
Hougeir, FG | 1 |
Feldman, SR; Moustafa, FA; Sandoval, LF | 1 |
Belasco, KT; Cadena, MJ; Friedrichs, A; Hinek, A; Hong, HC; Hougier, F; Jackson, JM; Johnson, SM; Kerdel, FA; Palceski, D; Tanghetti, EA | 1 |
Carter, B; Charland, L; Fedorowicz, Z; van der Linden, MM; van Zuuren, EJ | 1 |
Fowler, J; Jarratt, M; Leoni, M; Liu, Y; Meadows, K; Moore, A; Pollack, A; Steinhoff, M | 1 |
Fallen, RS; Gooderham, M | 1 |
4 review(s) available for quinoxalines and Rosacea
Article | Year |
---|---|
Brimonidine tartrate for the treatment of facial flushing and erythema in rosacea.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Brimonidine Tartrate; Erythema; Humans; Quality of Life; Quinoxalines; Rosacea; Treatment Outcome | 2014 |
Rosacea: new and emerging treatments.
Topics: Administration, Cutaneous; Brimonidine Tartrate; Dermatologic Agents; Drug Design; Humans; Ivermectin; Oxymetazoline; Quality of Life; Quinoxalines; Randomized Controlled Trials as Topic; Rosacea | 2014 |
Brimonidine for erythema caused by rosacea.
Topics: Adrenergic alpha-2 Receptor Agonists; Brimonidine Tartrate; Contraindications; Drug Costs; Drug Interactions; Erythema; Humans; Quinoxalines; Rosacea | 2014 |
Interventions for rosacea.
Topics: Anti-Infective Agents; Brimonidine Tartrate; Cyclosporine; Dermatologic Agents; Dicarboxylic Acids; Doxycycline; Female; Humans; Ivermectin; Male; Metronidazole; Middle Aged; Ophthalmic Solutions; Quinoxalines; Randomized Controlled Trials as Topic; Rosacea; Tetracycline | 2015 |
5 trial(s) available for quinoxalines and Rosacea
Article | Year |
---|---|
Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Brimonidine Tartrate; Dermatologic Agents; Double-Blind Method; Facial Dermatoses; Female; Follow-Up Studies; Gels; Humans; Male; Middle Aged; Quinoxalines; Rosacea; Severity of Illness Index; Time Factors; Treatment Outcome; Young Adult | 2013 |
Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study.
Topics: Administration, Cutaneous; Administration, Topical; Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Brimonidine Tartrate; Erythema; Face; Female; Humans; Male; Middle Aged; Quinoxalines; Rosacea; Social Behavior; Treatment Outcome; Young Adult | 2014 |
Comparative pharmacokinetics and bioavailability of brimonidine following ocular and dermal administration of brimonidine tartrate ophthalmic solution and gel in patients with moderate-to-severe facial erythema associated with rosacea.
Topics: Administration, Cutaneous; Adrenergic alpha-2 Receptor Agonists; Adult; Area Under Curve; Biological Availability; Brimonidine Tartrate; Drug Administration Schedule; Facial Dermatoses; Female; Gels; Humans; Male; Ophthalmic Solutions; Quinoxalines; Rosacea | 2014 |
Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Brimonidine Tartrate; Dermatologic Agents; Double-Blind Method; Erythema; Female; Gels; Humans; Male; Middle Aged; Quinoxalines; Rosacea; Severity of Illness Index; Time Factors; Treatment Outcome; Young Adult | 2014 |
Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies.
Topics: Administration, Cutaneous; Adolescent; Adrenergic alpha-2 Receptor Agonists; Adult; Aged; Brimonidine Tartrate; Dermatologic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Erythema; Facial Dermatoses; Female; Gels; Humans; Male; Middle Aged; Quinoxalines; Rosacea; Treatment Outcome; Young Adult | 2012 |
10 other study(ies) available for quinoxalines and Rosacea
Article | Year |
---|---|
Brimonidine gel (Mirvaso) for rosacea.
Topics: Adrenergic alpha-2 Receptor Agonists; Brimonidine Tartrate; Drug Approval; Gels; Humans; Quinoxalines; Randomized Controlled Trials as Topic; Rosacea; Treatment Outcome; United States; United States Food and Drug Administration | 2013 |
Management of facial erythema of rosacea: what is the role of topical α-adrenergic receptor agonist therapy?
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Brimonidine Tartrate; Erythema; Humans; Oxymetazoline; Quinoxalines; Rosacea; Sympathetic Nervous System; Vasodilation | 2013 |
Rebound erythema and burning sensation from a new topical brimonidine tartrate gel 0.33%.
Topics: Administration, Cutaneous; Adult; Brimonidine Tartrate; Dose-Response Relationship, Drug; Drug Administration Schedule; Erythema; Female; Follow-Up Studies; Gels; Humans; Pain; Quinoxalines; Recurrence; Risk Assessment; Rosacea; Sampling Studies; Severity of Illness Index | 2014 |
Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 5: a guide on the management of rosacea.
Topics: Administration, Cutaneous; Administration, Oral; Adrenergic alpha-2 Receptor Agonists; Anti-Infective Agents; Brimonidine Tartrate; Consensus; Dermatologic Agents; Dicarboxylic Acids; Doxycycline; Erythema; Humans; Metronidazole; Quinoxalines; Rosacea; Severity of Illness Index; Societies, Medical | 2014 |
Brimonidine effective but may lead to significant rebound erythema.
Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Brimonidine Tartrate; Erythema; Female; Humans; Quinoxalines; Rosacea; Vasoconstriction | 2014 |
Optical coherence tomography imaging of erythematotelangiectatic rosacea during treatment with brimonidine topical gel 0.33%: a potential method for treatment outcome assessment.
Topics: Administration, Cutaneous; Adrenergic alpha-2 Receptor Agonists; Adult; Brimonidine Tartrate; Female; Gels; Humans; Quinoxalines; Rosacea; Severity of Illness Index; Tomography, Optical Coherence; Treatment Outcome | 2014 |
New agents for the treatment of erythematotelangiectatic rosacea.
Topics: Brimonidine Tartrate; Clinical Trials as Topic; Dermatologic Agents; Gels; Humans; Oxymetazoline; Quinoxalines; Rosacea; Treatment Outcome | 2014 |
[Erythema of rosacea: a new and effective treatment].
Topics: Adrenergic alpha-2 Receptor Agonists; Brimonidine Tartrate; Erythema; Female; Humans; Male; Middle Aged; Quinoxalines; Rosacea; Treatment Outcome | 2014 |
Optimizing the use of topical brimonidine in rosacea management: panel recommendations.
Topics: Administration, Cutaneous; Adrenergic alpha-2 Receptor Agonists; Brimonidine Tartrate; Dermatologic Agents; Gels; Humans; Quinoxalines; Rosacea; Treatment Outcome | 2015 |
Rosacea: update on management and emerging therapies.
Topics: Administration, Cutaneous; Adrenergic Agents; Anti-Infective Agents; Antiparasitic Agents; Brimonidine Tartrate; Dermatologic Agents; Dicarboxylic Acids; Doxycycline; Female; Humans; Ivermectin; Male; Metronidazole; Oxymetazoline; Quality of Life; Quinoxalines; Randomized Controlled Trials as Topic; Rosacea; Sulfacetamide; Treatment Outcome | 2012 |